Skip to content

Family Planning Ahead

Family Planning Ahead

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03500952
Enrollment
41
Registered
2018-04-18
Start date
2018-03-22
Completion date
2018-08-23
Last updated
2019-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contraception, Pregnancy Related

Brief summary

Family Planning Ahead is a study that aims to improve decision-making about postpartum contraception. Family Planning Ahead will test two different strategies: a patient decision aid and a patient information leaflet.

Interventions

OTHERBirth Control After Pregnancy

A 27-page patient decision aid in portable document format (and an accompanying 3-page supporting document in portable document format) hosted online.

OTHERPostpartum Birth Control

A 4-page patient information leaflet in portable document format and text format hosted online.

Sponsors

Dartmouth-Hitchcock Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
15 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Currently pregnant * Between 28 and 38 weeks' gestation at the time of enrollment * Estimated due date in March, April, May, or June 2018 * 15 years or older * Can read and write English * Live in the United States * Share a valid email address for study purposes

Exclusion criteria

* Not currently pregnant * Less than 28 weeks' or more than 38 weeks' gestation at the time of enrollment * Estimated due date earlier than March 2018 or later than June 2018 * Under 15 years * Can not read and write English * Do not live in the United States * Do not share a valid email address for study purposes

Design outcomes

Primary

MeasureTime frameDescription
Perceived support in decision-makingT2 (Approximately 7-11 weeks after self-reported estimated due date)The extent to which the person feels they received adequate support and advice without pressure to make a decision about postpartum contraceptive methods, measured using adapted versions of the Support subscale of the Decisional Conflict Scale (O'Connor, 1993).

Secondary

MeasureTime frameDescription
Values clarityT0 (immediately following study enrollment); T1 (one week following study enrollment)The extent to which the person feels clear about personal values related to postpartum contraceptive method benefits, risks, and side effects, measured using an adapted version of the Values Clarity subscale of the Decisional Conflict Scale (O'Connor, 1993).
Decisional uncertaintyT0 (immediately following study enrollment); T1 (one week following study enrollment)The extent to which the person feels certain about which postpartum contraceptive method to choose, measured using an adapted version of the Uncertainty subscale of the Decisional Conflict Scale (O'Connor, 1993).
Decision self-efficacyT0 (immediately following study enrollment); T1 (one week following study enrollment)The extent to which the person has self-confidence or belief in their ability to make decisions about postpartum contraceptive methods, measured using an adapted version of the Decision Self-Efficacy Scale (O'Connor, 1995).
Intended contraceptive method(s): LARC vs. otherT0 (immediately following study enrollment); T1 (one week following study enrollment)The proportion of people who intend to use a long-acting reversible contraceptive (LARC) method (i.e., hormonal intrauterine device, copper intrauterine device, or implant) 'in the first few months after giving birth', measured using a self-developed item.
Intended contraceptive method(s): Most or moderately effective vs. otherT0 (immediately following study enrollment); T1 (one week following study enrollment)The proportion of people who intend to use a most or moderately effective contraceptive method (i.e., female sterilization, hormonal intrauterine device, copper intrauterine device, implant, injection, combined pill, progestin-only pill, patch, ring, diaphragm) 'in the first few months after giving birth', measured using a self-developed item.
Intended contraceptive method(s): Method vs. no method or unsureT0 (immediately following study enrollment); T1 (one week following study enrollment)The proportion of people who intend to use one or more contraceptive methods (i.e., female sterilization, hormonal intrauterine device, copper intrauterine device, implant, injection, combined pill, progestin-only pill, patch, ring, diaphragm, male condom, internal (female) condom, spermicide, sponge, cervical cap, lactational amenorrhea method, withdrawal, fertility awareness, male sterilization, and/or emergency contraceptive pill) 'in the first few months after giving birth', measured using a self-developed item.
Intended timing of contraceptive method(s) initiation: Not unsure vs. unsureT0 (immediately following study enrollment); T1 (one week following study enrollment)The proportion of people who are not unsure about how soon after giving birth they will (first) start using a contraceptive method (i.e., intend to start using a contraceptive method 'in the first 10 minutes', 'in the first few days', 'in the first few weeks', 'around 6 weeks', 'in the first few months' or 'other'), measured using a self-developed item.
Values concordance of intended contraceptive method(s)T0 (immediately following study enrollment); T1 (one week following study enrollment)The proportion of people who perceive optimal values concordance of their intended postpartum contraceptive method(s) (or intention to use no contraceptive methods), measured using the Measure of Alignment of Choices (Thompson et al., 2017).
Trust in health professional(s)T2 (Approximately 7-11 weeks after self-reported estimated due date)The extent to which the person feels trust in the health professional(s) they talk to about postpartum contraception during and/or after pregnancy, measured using an adapted version of the Patient Trust in a Physician Scale (Dugan et al., 2005).
Interpersonal quality of family planning careT2 (Approximately 7-11 weeks after self-reported estimated due date)The proportion of people who report high interpersonal quality of family planning care during and/or after pregnancy, measured using an adapted version of the four-item Interpersonal Quality of Family Planning Care (IQFP-R) scale (Dehlendorf et al. 2016).
Shared decision-makingT2 (Approximately 7-11 weeks after self-reported estimated due date)The extent to which which the person feels they experienced shared decision-making about postpartum contraceptive methods during and/or after pregnancy, measured using the CollaboRATE measure (Barr et al., 2014).
Concordance between preferred and actual decision-making involvement (self): Concordant vs. discordantT2 (Approximately 7-11 weeks after self-reported estimated due date)The proportion of people who report concordance between their actual and preferred involvement in the decision to use their postpartum contraceptive method(s), measured using two self-developed items.
Concordance between preferred and actual decision-making involvement (partner): Concordant vs. discordantT2 (Approximately 7-11 weeks after self-reported estimated due date)The proportion of people who report concordance between the actual involvement of their partner and their preferences pertaining to partner involvement in the decision to use their postpartum contraceptive method(s), measured using two self-developed items.
Concordance between preferred and actual decision-making involvement (health professional(s)): Concordant vs. discordantT2 (Approximately 7-11 weeks after self-reported estimated due date)The proportion of people who report concordance between the actual involvement of their health professional(s) and their preferences pertaining to health professional involvement in the decision to use their postpartum contraceptive method(s), measured using two self-developed items.
Perceptions of being informedT0 (immediately following study enrollment); T1 (one week following study enrollment)The extent to which the person feels informed of available postpartum contraceptive methods and the benefits, risks, and side effects of each, measured using an adapted version of the Informed subscale of the Decisional Conflict Scale (O'Connor, 1993).
Pressure to use a certain contraceptive methodT2 (Approximately 7-11 weeks after self-reported estimated due date)The extent to which the person felt (or feels) pushed to use a certain postpartum contraceptive method, measured using a self-developed item.
Values concordance of contraceptive method(s) usedT2 (Approximately 7-11 weeks after self-reported estimated due date)The proportion of people who perceive optimal values concordance of the postpartum contraceptive method(s) they have used, measured using the Measure of Alignment of Choices (Thompson et al., 2017).
Effective decisionT2 (Approximately 7-11 weeks after self-reported estimated due date)The extent to which the person feels they made an effective decision about postpartum contraceptive methods, measured using an adapted version of the Effective Decision subscale of the Decisional Conflict Scale (O'Connor, 1993).
Contraceptive method(s) prescribed in first 60 days: LARC vs. otherT2 (Approximately 7-11 weeks after self-reported estimated due date)The proportion of people who report being given or prescribed a long-acting reversible contraceptive (LARC) method (i.e., hormonal intrauterine device, copper intrauterine device, or implant) in the first 60 days after giving birth, measured using a self-developed item.
Contraceptive method(s) prescribed in first 60 days: Most or moderately effective vs. otherT2 (Approximately 7-11 weeks after self-reported estimated due date)The proportion of people who report being given or prescribed a most or moderately effective contraceptive method (i.e., female sterilization, hormonal intrauterine device, copper intrauterine device, implant, injection, combined pill, progestin-only pill, patch, ring, diaphragm) in the first 60 days after giving birth, measured using a self-developed item.
Contraceptive method(s) prescribed in first 3 days: LARC vs. otherT2 (Approximately 7-11 weeks after self-reported estimated due date)The proportion of people who report being given or prescribed a long-acting reversible contraceptive (LARC) method (i.e., hormonal intrauterine device, copper intrauterine device, or implant) in the first 3 days after giving birth, measured using a self-developed item.
Contraceptive method(s) prescribed in first 3 days: Most or moderately effective vs. otherT2 (Approximately 7-11 weeks after self-reported estimated due date)The proportion of people who report being given or prescribed a most or moderately effective contraceptive method (i.e., female sterilization, hormonal intrauterine device, copper intrauterine device, implant, injection, combined pill, progestin-only pill, patch, ring, diaphragm) in the first 3 days after giving birth, measured using a self-developed item.
Contraceptive method(s) used: LARC vs. otherT2 (Approximately 7-11 weeks after self-reported estimated due date)The proportion of people who, at the time of survey completion, report having used a long-acting reversible contraceptive (LARC) method (i.e., hormonal intrauterine device, copper intrauterine device, or implant) since giving birth, measured using a self-developed item.
Contraceptive method(s) used: Most or moderately effective vs. otherT2 (Approximately 7-11 weeks after self-reported estimated due date)The proportion of people who, at the time of survey completion, report having used a most or moderately effective contraceptive method (i.e., female sterilization, hormonal intrauterine device, copper intrauterine device, implant, injection, combined pill, progestin-only pill, patch, ring, diaphragm) since giving birth, measured using a self-developed item.
Contraceptive method(s) used: Method vs. no methodT2 (Approximately 7-11 weeks after self-reported estimated due date)The proportion of people who, at the time of survey completion, report having used one or more contraceptive methods (i.e., female sterilization, hormonal intrauterine device, copper intrauterine device, implant, injection, combined pill, progestin-only pill, patch, ring, diaphragm, male condom, internal (female) condom, spermicide, sponge, cervical cap, lactational amenorrhea method, withdrawal, fertility awareness, male sterilization, and/or emergency contraceptive pill) since giving birth, measured using a self-developed item.
Timing of decision about contraceptive method(s): During pregnancy vs. since giving birthT2 (Approximately 7-11 weeks after self-reported estimated due date)The proportion of people who report deciding to use their postpartum contraceptive method(s) during pregnancy, measured using a self-developed item.
Likelihood of recommending the intervention to a friendT1 (one week following study enrollment)The proportion of people who report that they are extremely likely to recommend the intervention to a friend, measured using a self-developed item.
Likelihood of reviewing the intervention in the futureT1 (one week following study enrollment)The proportion of people who report that they are extremely likely to review the intervention in the future, measured using a self-developed item.
Perceived utility of the interventionT1 (one week following study enrollment)The extent to which the person perceives that the intervention was useful in preparing them to communicate with their health professional and make a decision, measured using an adapted version of the Preparation for Decision Making Scale (Graham & O'Connor, 2010).
Time pressure in decision-makingT2 (Approximately 7-11 weeks after self-reported estimated due date)The extent to which the person feels they had (or have) enough time to make a decision about postpartum contraceptive methods, measured using a self-developed item.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026